{"id":"W3028860151","doi":"10.1200/jco.2020.38.15_suppl.3063","title":"Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Response Evaluation Criteria in Solid Tumors; Internal medicine; Monoclonal antibody; Oncology; Immune system; Progressive disease; Antibody; Gastroenterology; Phases of clinical research; Clinical trial; Immunology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001156905,0.0007941482,0.001399367,0.0003590014,0.0003215313,0.0007732055,0.0004051271,0.0006893477,0.001316351],"category_scores_gemma":[0.0007950887,0.0003816627,0.0008222425,0.0004710201,0.0005238596,0.0005290771,0.0002959543,0.001636294,0.0004418776],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001006178,"about_ca_system_score_gemma":0.001032793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007248106,"about_ca_topic_score_gemma":0.0015632,"domain_scores_codex":[0.9995853,0.0001975034,0.00004370451,0.00006187133,0.00005611278,0.00005549825],"domain_scores_gemma":[0.9994454,0.0001418758,0.0001752578,0.00004203143,0.00003027358,0.0001652331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4674171,0.01495274,0.03305873,0.002127246,0.002681375,0.0006214926,0.0006455786,0.005782838,0.1259192,0.0004412846,0.005112559,0.3412398],"study_design_scores_gemma":[0.2955726,0.5925183,0.06907633,0.0002073281,0.002251518,0.001519668,0.0001115211,0.003268725,0.02244874,0.0003493976,0.01260928,0.00006661213],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887944,0.007994541,0.0004603188,0.0003270877,0.00005009542,0.0004261413,0.0004162661,0.00004660162,0.00148437],"genre_scores_gemma":[0.9957981,0.001882538,0.0005560214,0.0002603673,0.00006626261,0.0002803373,0.0006422193,0.000008030598,0.0005061445],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001399367,"threshold_uncertainty_score":0.007300317,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0470041413415561,"score_gpt":0.4177542274816552,"score_spread":0.3707500861400991,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}